{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=oxymorphone+HCl", "query": { "intervention": "oxymorphone HCl" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 22, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=oxymorphone+HCl&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-11T05:51:45.885Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00225797", "title": "Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Pain" ], "interventions": [ { "name": "Oxymorphone Extended Release", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Endo USA Inc., a Keenova Therapeutics Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2004-11", "completion_date": "2005-07", "has_results": false, "last_update_posted_date": "2024-01-02", "last_synced_at": "2026-09-11T05:51:45.885Z", "location_count": 33, "location_summary": "Hueytown, Alabama • Phoenix, Arizona • Colorado Springs, Colorado + 27 more", "locations": [ { "city": "Hueytown", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Bridgeport", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00225797" }, { "nct_id": "NCT03579446", "title": "Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Hematopoietic and Lymphoid Cell Neoplasm", "Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm" ], "interventions": [ { "name": "Hydrocodone", "type": "DRUG" }, { "name": "Hydromorphone", "type": "DRUG" }, { "name": "Levorphanol", "type": "DRUG" }, { "name": "Morphine", "type": "DRUG" }, { "name": "Oxycodone", "type": "DRUG" }, { "name": "Oxymorphone", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2018-11-29", "completion_date": "2023-06-15", "has_results": false, "last_update_posted_date": "2025-08-03", "last_synced_at": "2026-09-11T05:51:45.885Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03579446" }, { "nct_id": "NCT02625181", "title": "Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Postoperative Nausea and Vomiting" ], "interventions": [ { "name": "Automated recommendation at the start of the case", "type": "PROCEDURE" }, { "name": "Automated notification at the start of surgery", "type": "PROCEDURE" }, { "name": "Preoperative recommendations: by email", "type": "PROCEDURE" }, { "name": "Automated notification at the end of surgery", "type": "PROCEDURE" }, { "name": "Anesthesia Information Management System (AIMS)", "type": "DEVICE" }, { "name": "Perioperative Data Warehouse (PDW)", "type": "DEVICE" }, { "name": "General anesthesia", "type": "PROCEDURE" }, { "name": "Elective surgery", "type": "PROCEDURE" }, { "name": "Propofol", "type": "DRUG" }, { "name": "Sevoflurane", "type": "DRUG" }, { "name": "Isoflurane", "type": "DRUG" }, { "name": "Desflurane", "type": "DRUG" }, { "name": "Scopolamine", "type": "DRUG" }, { "name": "Droperidol", "type": "DRUG" }, { "name": "Haloperidol", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Promethazine", "type": "DRUG" }, { "name": "Meclizine", "type": "DRUG" }, { "name": "Aprepitant", "type": "DRUG" }, { "name": "Metoclopramide", "type": "DRUG" }, { "name": "Fentanyl", "type": "DRUG" }, { "name": "Sufentanil", "type": "DRUG" }, { "name": "Alfentanil", "type": "DRUG" }, { "name": "Remifentanil", "type": "DRUG" }, { "name": "Morphine", "type": "DRUG" }, { "name": "Meperidine", "type": "DRUG" }, { "name": "Hydromorphone", "type": "DRUG" }, { "name": "Methadone", "type": "DRUG" }, { "name": "Oxycodone", "type": "DRUG" }, { "name": "Oxymorphone", "type": "DRUG" }, { "name": "Hydrocodone", "type": "DRUG" }, { "name": "Ketamine", "type": "DRUG" }, { "name": "Ondansetron", "type": "DRUG" }, { "name": "Granisetron", "type": "DRUG" }, { "name": "Dolasetron mesylate", "type": "DRUG" }, { "name": "Palonosetron", "type": "DRUG" }, { "name": "Tropisetron", "type": "DRUG" }, { "name": "Ramosetron", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DEVICE", "DRUG" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27034, "start_date": "2016-07", "completion_date": "2017-11-30", "has_results": true, "last_update_posted_date": "2019-03-07", "last_synced_at": "2026-09-11T05:51:45.885Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02625181" }, { "nct_id": "NCT00930943", "title": "Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Pain" ], "interventions": [ { "name": "Oxymorphone ER", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedVadis Research Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2009-05", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2023-05-09", "last_synced_at": "2026-09-11T05:51:45.885Z", "location_count": 1, "location_summary": "Wellesley Hills, Massachusetts", "locations": [ { "city": "Wellesley Hills", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00930943" }, { "nct_id": "NCT00765856", "title": "Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Pain" ], "interventions": [ { "name": "Oxymorphone ER", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Endo USA Inc., a Keenova Therapeutics Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 27, "start_date": "2008-11-17", "completion_date": "2010-02-22", "has_results": true, "last_update_posted_date": "2020-12-16", "last_synced_at": "2026-09-11T05:51:45.885Z", "location_count": 13, "location_summary": "Little Rock, Arkansas • Stanford, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00765856" }, { "nct_id": "NCT00801398", "title": "Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Postoperative Pain" ], "interventions": [ { "name": "Oxymorphone IR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Endo USA Inc., a Keenova Therapeutics Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 58, "start_date": "2009-02-17", "completion_date": "2011-04-18", "has_results": true, "last_update_posted_date": "2019-02-27", "last_synced_at": "2026-09-11T05:51:45.885Z", "location_count": 11, "location_summary": "Little Rock, Arkansas • Stanford, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00801398" }, { "nct_id": "NCT01210638", "title": "Bioequivalency Study of Oxymorphone Hydrochloride 10 mg Tablets Under Fasted Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pain" ], "interventions": [ { "name": "Oxymorphone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roxane Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 42, "start_date": "2008-06", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2018-01-23", "last_synced_at": "2026-09-11T05:51:45.885Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01210638" }, { "nct_id": "NCT04681027", "title": "Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced Children", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Pain", "Postsurgical Pain" ], "interventions": [ { "name": "Oxymorphone hydrochloride (HCl)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Endo USA Inc., a Keenova Therapeutics Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "7 Years to 17 Years" }, "enrollment_count": 15, "start_date": "2013-03-11", "completion_date": "2021-01", "has_results": false, "last_update_posted_date": "2020-12-23", "last_synced_at": "2026-09-11T05:51:45.885Z", "location_count": 5, "location_summary": "Orange, California • New Orleans, Louisiana • Oklahoma City, Oklahoma + 2 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04681027" }, { "nct_id": "NCT01928303", "title": "Predicting Oxycodone Dose From Oral Fluid Drug Levels", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Pain" ], "interventions": [], "intervention_types": [], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 55, "start_date": "2013-03", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2014-09-15", "last_synced_at": "2026-09-11T05:51:45.885Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01928303" }, { "nct_id": "NCT01210352", "title": "Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Post Operative Pain" ], "interventions": [ { "name": "oxymorphone HCl", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Endo USA Inc., a Keenova Therapeutics Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "12 Years", "sex": "ALL", "summary": "0 Years to 12 Years" }, "enrollment_count": 61, "start_date": "2010-12-13", "completion_date": "2017-10-06", "has_results": true, "last_update_posted_date": "2021-08-20", "last_synced_at": "2026-09-11T05:51:45.885Z", "location_count": 8, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Aurora, Colorado + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01210352" } ] }